Plastic Surgery Unit, Department of Medical Biotechnology and Translational Medicine BIOMETRA, Humanitas Clinical and Research Hospital, Reconstructive and Aesthetic Plastic Surgery School, University of Milan, Via Manzoni 56, Rozzano, Milan 20090, Italy.
Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy.
Biomed Res Int. 2020 Oct 16;2020:3261318. doi: 10.1155/2020/3261318. eCollection 2020.
Acellular dermal matrix (ADM) products are adopted in the management of injuries to soft tissues. ADMs have been increasingly employed for their clinical advantages, and they are acquiring relevance in the future of plastic surgery. The aim of our study is to evaluate the application of ADMs in our patients who could not undergo fast reconstruction.
We performed a retrospective study on 12 patients who underwent ADM placement for scalp and limb surgical reconstructions at the Humanitas Research Hospital, Rozzano (Milano), Italy. Wounds resulted from 9 tumor resections and 3 chronic ulcers. The ADM substrate used to treat these lesions was PELNAC™ (Gunze, Japan), a double-layered matrix composed of atelocollagen porcine tendon and silicon reinforcement. All patients underwent a second surgical operation to complete the treatment with a full-thickness skin graft to cover the lesion.
In this study, 12 patients were treated with PELNAC™: 11 out of 12 patients showed a good attachment over a median time of 21.3 days (range 14-27). After almost 23 days, all patients were ready to undergo a full-thickness skin grafting.
This study assesses the benefits of PELNAC™ and proposes this method as an alternative to traditional approaches, especially in situations where the latter techniques cannot be applied.
脱细胞真皮基质 (ADM) 产品被用于软组织损伤的处理。ADM 因其临床优势而被越来越多地采用,并且在未来的整形手术中具有相关性。我们的研究目的是评估 ADM 在我们无法进行快速重建的患者中的应用。
我们对在意大利米兰罗扎诺的 Humanitas 研究医院接受头皮和四肢手术重建的 12 名患者进行了回顾性研究。这些伤口是由 9 例肿瘤切除术和 3 例慢性溃疡引起的。用于治疗这些病变的 ADM 基质是 PELNAC™(日本 Gunze),这是一种由原胶原蛋白猪肌腱和硅增强材料组成的双层基质。所有患者均进行了第二次手术,以全厚皮片移植覆盖病变,完成治疗。
在这项研究中,12 名患者使用了 PELNAC™:12 名患者中有 11 名在 21.3 天的中位时间内(14-27 天)显示出良好的附着。在将近 23 天后,所有患者都准备好接受全厚皮片移植。
本研究评估了 PELNAC™ 的益处,并提出了这种方法作为传统方法的替代方法,特别是在后者技术无法应用的情况下。